FGEN Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of -36.87% compared to FibroGen's net margin of 14.23%. FibroGen's return on equity of -- beat Biomarin Pharmaceutical's return on equity of 6.29%.

FibroGen has a consensus price target of $10.00, signalling upside risk potential of 2400%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $98.08 which suggests that it could grow by 49.31%. Given that FibroGen has higher upside potential than Biomarin Pharmaceutical, analysts believe FibroGen is more attractive than Biomarin Pharmaceutical.

FibroGen has a beta of 0.823, which suggesting that the stock is 17.658% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.295, suggesting its less volatile than the S&P 500 by 70.544%.

FibroGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FibroGen pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

FibroGen quarterly revenues are $46.3M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.7M. FibroGen's net income of -$17.1M is lower than Biomarin Pharmaceutical's net income of $106.1M. Notably, FibroGen's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 39.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FibroGen is 0.22x versus 4.69x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Cidara Therapeutics has a net margin of -36.87% compared to FibroGen's net margin of -30201.66%. FibroGen's return on equity of -- beat Cidara Therapeutics's return on equity of -443.37%.

FibroGen has a consensus price target of $10.00, signalling upside risk potential of 2400%. On the other hand Cidara Therapeutics has an analysts' consensus of -- which suggests that it could grow by 24.89%. Given that FibroGen has higher upside potential than Cidara Therapeutics, analysts believe FibroGen is more attractive than Cidara Therapeutics.

FibroGen has a beta of 0.823, which suggesting that the stock is 17.658% less volatile than S&P 500. In comparison Cidara Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.883%.

FibroGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cidara Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FibroGen pays -- of its earnings as a dividend. Cidara Therapeutics pays out -- of its earnings as a dividend.

FibroGen quarterly revenues are $46.3M, which are larger than Cidara Therapeutics quarterly revenues of $302K. FibroGen's net income of -$17.1M is lower than Cidara Therapeutics's net income of -$16M. Notably, FibroGen's price-to-earnings ratio is -- while Cidara Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FibroGen is 0.22x versus 1.91x for Cidara Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Cue Biopharma has a net margin of -36.87% compared to FibroGen's net margin of -259.59%. FibroGen's return on equity of -- beat Cue Biopharma's return on equity of -142.28%.

FibroGen has a consensus price target of $10.00, signalling upside risk potential of 2400%. On the other hand Cue Biopharma has an analysts' consensus of $4.20 which suggests that it could grow by 251.22%. Given that FibroGen has higher upside potential than Cue Biopharma, analysts believe FibroGen is more attractive than Cue Biopharma.

FibroGen has a beta of 0.823, which suggesting that the stock is 17.658% less volatile than S&P 500. In comparison Cue Biopharma has a beta of 1.658, suggesting its more volatile than the S&P 500 by 65.823%.

FibroGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cue Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FibroGen pays -- of its earnings as a dividend. Cue Biopharma pays out -- of its earnings as a dividend.

FibroGen quarterly revenues are $46.3M, which are larger than Cue Biopharma quarterly revenues of $3.3M. FibroGen's net income of -$17.1M is lower than Cue Biopharma's net income of -$8.7M. Notably, FibroGen's price-to-earnings ratio is -- while Cue Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FibroGen is 0.22x versus 5.32x for Cue Biopharma. Usually stocks with elevated PS ratios are considered overvalued.

GlycoMimetics has a net margin of -36.87% compared to FibroGen's net margin of --. FibroGen's return on equity of -- beat GlycoMimetics's return on equity of --.

FibroGen has a consensus price target of $10.00, signalling upside risk potential of 2400%. On the other hand GlycoMimetics has an analysts' consensus of -- which suggests that it could grow by 327.9%. Given that FibroGen has higher upside potential than GlycoMimetics, analysts believe FibroGen is more attractive than GlycoMimetics.

FibroGen has a beta of 0.823, which suggesting that the stock is 17.658% less volatile than S&P 500. In comparison GlycoMimetics has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.069%.

FibroGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GlycoMimetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. FibroGen pays -- of its earnings as a dividend. GlycoMimetics pays out -- of its earnings as a dividend.

FibroGen quarterly revenues are $46.3M, which are larger than GlycoMimetics quarterly revenues of --. FibroGen's net income of -$17.1M is lower than GlycoMimetics's net income of -$9.8M. Notably, FibroGen's price-to-earnings ratio is -- while GlycoMimetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for FibroGen is 0.22x versus -- for GlycoMimetics. Usually stocks with elevated PS ratios are considered overvalued.